P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY CO-INHIBITING THE B2 AND B1 PROTEASOME SUBUNITS

• X. Zhou,
• A. Besse,
• J. Peter,
• M. J. Steinhardt,
• C. Vogt,
• S. Nerreter,
• E. Teufel,
• E. Stanojkovska,
• X. Xiao,
• H. Hornburger,
• L. Haertle,
• M. Mendez Lopez,
• U. Munawar,
• A. Riedel,
• S. Han,
• E. Maurits,
• H. S. Overkleeft,
• B. Florea,
• H. Einsele,
• K. M. Kortüm,
• C. Driessen,
• L. Besse,
• L. Rasche

Affiliations

X. Zhou

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

A. Besse

2 Experimental Oncology and Hematology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

J. Peter

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

M. J. Steinhardt

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

C. Vogt

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

S. Nerreter

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

E. Teufel

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

E. Stanojkovska

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

X. Xiao

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

H. Hornburger

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

L. Haertle

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

M. Mendez Lopez

2 Experimental Oncology and Hematology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

U. Munawar

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

A. Riedel

3 Mildred Scheel Early Career Center, University of Würzburg, Würzburg, Germany

S. Han

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

E. Maurits

4 Gorlaeus Laboratories, Leiden Institute of Chemistry and Netherlands Proteomics Centre, Leiden, the Netherlands

H. S. Overkleeft

4 Gorlaeus Laboratories, Leiden Institute of Chemistry and Netherlands Proteomics Centre, Leiden, the Netherlands

B. Florea

4 Gorlaeus Laboratories, Leiden Institute of Chemistry and Netherlands Proteomics Centre, Leiden, the Netherlands

H. Einsele

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

K. M. Kortüm

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

C. Driessen

2 Experimental Oncology and Hematology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

L. Besse

2 Experimental Oncology and Hematology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

L. Rasche

1 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany